中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

16 records (took 0.019 seconds)

    APPARATUS AND METHOD FOR CLEANING SURFACES
    1.
    发明申请
    APPARATUS AND METHOD FOR CLEANING SURFACES 审中-公开

    公开(公告)号：WO2009142774A3

    公开(公告)日：2009-11-26

    申请号：PCT/US2009/003194

    申请日：2009-05-22

    Applicant: FIFTH GENERATION SOLAR ,  PIETSCH, Anton ,  LYNCH, George ,  LYNCH, Kevin ,  CHANG, George

    Inventor： PIETSCH, Anton ,  LYNCH, George ,  LYNCH, Kevin ,  CHANG, George

    IPC: A47L7/00

    Abstract: The apparatus for cleaning surfaces of the present invention such as for cleaning solar collectors preferably alternates different fluids and gas decompression to create a cleansing fluid evacuation to clean outdoor solid surfaces. The method of the present invention utilizes alternating fluids in order to avoid mineral deposits contaminating the collector. The apparatus of the present invention is a tool to achieve the ends of the method. The apparatus preferably uses copper piping and turbulence to regulate water flow and to create the high velocity fluid evacuation that achieves the ends of the method invention. The use of a constant pressure pump and turbulence inducing fibers allows passive regulation of pressure that is equalized across a plurality of sprayers to deliver an even amount of high velocity fluid from each sprayer. Sonication accelerates cleaning, rinsing or snow/ice removal.

    1, 3-OXAZOLE DERIVATIVES AS CETP INHIBITORS
    3.
    发明申请
    1, 3-OXAZOLE DERIVATIVES AS CETP INHIBITORS 审中-公开
    1,3-氧杂衍生物作为CETP抑制剂

    公开(公告)号：WO2009027785A3

    公开(公告)日：2009-09-17

    申请号：PCT/IB2008002164

    申请日：2008-08-18

    Applicant: PFIZER PROD INC ,  CHANG GEORGE ,  GARIGIPATI RAVI SHANKER ,  PERRY DAVID AUSTEN

    Inventor： CHANG GEORGE ,  GARIGIPATI RAVI SHANKER ,  PERRY DAVID AUSTEN

    IPC: C07D263/22 ,  A61K31/421 ,  A61P9/00

    CPC classification number: C07D263/22

    Abstract: Pharmaceutical compounds according to Formula I and derivatives, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans. Formula (I) or a pharmaceutically acceptable salt of said compound; wherein Formula (II) M and J are each independently CH2 or a bond wherein at least one of M and J are CH2.

    Abstract translation: 根据式I的药物化合物及其衍生物，含有这些化合物的药物组合物以及使用这些化合物来提升某些血浆脂质含量，包括高密度脂蛋白胆固醇和降低某些其它血浆脂质水平，如LDL-胆固醇和甘油三酸酯，以及 相应地治疗由于低水平的HDL胆固醇和/或高水平的LDL-胆固醇和甘油三酸酯而加重的疾病，例如包括人在内的一些哺乳动物的动脉粥样硬化和心血管疾病。 式（I）或所述化合物的药学上可接受的盐; 其中式（II）M和J各自独立地为CH 2或其中M和J中的至少一个为CH 2的键。

    TETRAHYDROISOQUINOLINE DERIVATIVES AS PPAR-α ACTIVATORS
    5.
    发明申请
    TETRAHYDROISOQUINOLINE DERIVATIVES AS PPAR-α ACTIVATORS 审中-公开
    四氢喹啉衍生物作为PPAR-α激活剂

    公开(公告)号：WO2004103997A1

    公开(公告)日：2004-12-02

    申请号：PCT/IB2004/001619

    申请日：2004-05-10

    Applicant: PFIZER PRODUCTS INC. ,  CHANG, George

    Inventor： CHANG, George

    IPC: C07D417/06

    CPC classification number: C07D417/06

    Abstract: PPAR alpha activators, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases, in mammals, including humans. Formula (I).

    Abstract translation: PPARα激活剂，含有这些化合物的药物组合物以及使用这些化合物来提高某些血浆脂质水平，包括高密度脂蛋白胆固醇和降低某些其他血浆脂质水平，如低密度脂蛋白胆固醇和甘油三酸酯，从而治疗 由哺乳动物（包括人类）中低密度脂蛋白胆固醇和/或高水平的低密度脂蛋白胆固醇和甘油三酯（如动脉粥样硬化和心血管疾病）而加剧。 式（I）。

    APO B-SECRETION/MTP INHIBITORY AMIDES
    6.
    发明申请
    APO B-SECRETION/MTP INHIBITORY AMIDES 审中-公开
    APO B分泌/ MTP抑制剂

    公开(公告)号：WO1998023593A1

    公开(公告)日：1998-06-04

    申请号：PCT/IB1997001368

    申请日：1997-11-03

    Applicant: PFIZER INC. ,  CHANG, George ,  QUALLICH, George, Joseph

    Inventor： PFIZER INC.

    IPC: C07D217/04

    CPC classification number: C07D401/04 ,  C07D217/04 ,  C07D401/06 ,  C07D405/04 ,  C07D405/06 ,  C07D409/06 ,  C07D417/06

    Abstract: This invention is directed to compounds of formula (I) or the stereoisomers, pharmaceutically acceptable salts and hydrates thereof. The compounds are Apo B/MTP inhibitors and are useful in the treatment of various disorders and conditions such as atherosclerosis, pancreatitis, obesity, hypercholesteremia, hypertriglyceridemia, hyperlipidemia, and diabetes. The compounds of this invention are also useful in combination with other pharmaceutical agents including cholesterol biosynthesis inhibitors and cholesterol absorption inhibitors, especially HMG-CoA reductase inhibitors and HMG-CoA synthase inhibitors; HMG-CoA reductase gene expression inhibitors; CETP inhibitors; bile acid sequestrants; fibrates; cholesterol absorption inhibitors; ACAT inhibitors, squalene synthetase inhibitors, ion-exchange resins, anti-oxidants and niacin. This invention is also directed to intermediates and processes useful in the preparation of compounds of formula (I).

    Abstract translation: 本发明涉及式（I）化合物或其立体异构体，其药学上可接受的盐和水合物。 这些化合物是Apo B / MTP抑制剂，可用于治疗各种疾病和病症如动脉粥样硬化，胰腺炎，肥胖症，高胆固醇血症，高甘油三酯血症，高脂血症和糖尿病。 本发明的化合物还可与其它药剂组合使用，包括胆固醇生物合成抑制剂和胆固醇吸收抑制剂，特别是HMG-CoA还原酶抑制剂和HMG-CoA合成酶抑制剂; HMG-CoA还原酶基因表达抑制剂; CETP抑制剂; 胆汁酸螯合剂 贝特类药物; 胆固醇吸收抑制剂; ACAT抑制剂，角鲨烯合成酶抑制剂，离子交换树脂，抗氧化剂和烟酸。 本发明还涉及可用于制备式（I）化合物的中间体和方法。

    SUBSTITUTED 1,1,1-TRIFLUORO-3-[(BENZYL)-(PYRIMIDIN-2-YL)-AMINO]-PROP AN-2-OL COMPOUNDS
    8.
    发明申请
    SUBSTITUTED 1,1,1-TRIFLUORO-3-[(BENZYL)-(PYRIMIDIN-2-YL)-AMINO]-PROP AN-2-OL COMPOUNDS 审中-公开
    取代的1,1,1-三氟-3 - [（苄基） - （吡咯烷-2-基） - 氨基] - 丙-2-醇化合物

    公开(公告)号：WO2006090250A1

    公开(公告)日：2006-08-31

    申请号：PCT/IB2006/000374

    申请日：2006-02-13

    Applicant: PFIZER PRODUCTS INC. ,  CHANG, George ,  PENCE, Michael Patrick

    Inventor： CHANG, George ,  PENCE, Michael Patrick

    IPC: C07D239/46 ,  A61K31/505 ,  A61P3/06

    CPC classification number: C07D239/47

    Abstract: Substituted 1,1,1-trifluoro-3-[(benzyl)-(pyrimidin-2-yl)-amino]-propan-2-ol compounds, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.

    Abstract translation: 取代的1,1,1-三氟-3 - [（苄基） - （嘧啶-2-基） - 氨基] - 丙-2-醇化合物，含有这些化合物的药物组合物和这些化合物用于提高某些血浆脂质 水平，包括高密度脂蛋白胆固醇和降低某些其他血浆脂质水平，如低密度脂蛋白胆固醇和甘油三酸酯，并因此治疗由低水平的HDL胆固醇和/或高水平的低密度脂蛋白胆固醇和甘油三酯加剧的疾病， 例如一些哺乳动物，包括人类的动脉粥样硬化和心血管疾病。

    BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION
    9.
    发明申请
    BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION 审中-公开
    联苯-2-羧酸 - 四氢异喹啉-6-YL酰胺衍生物，其制备及其作为微量TRIGLYCERIDE转移蛋白和/或APOLIPOPROTEIN B（Apo B）分泌物的抑制剂的用途

    公开(公告)号：WO1996040640A1

    公开(公告)日：1996-12-19

    申请号：PCT/IB1995000448

    申请日：1995-06-07

    Applicant: PFIZER INC. ,  CHANG, George ,  DORFF, Peter, H. ,  QUALLICH, George, J.

    Inventor： PFIZER INC.

    IPC: C07D217/04

    CPC classification number: C07D401/06 ,  C07D217/04 ,  C07D217/06 ,  C07D401/10 ,  C07D405/06 ,  C07D409/06 ,  C07D413/06 ,  C07D417/06

    Abstract: Compounds of formula (I), wherein X is CH2, CO, CS or SO2; Y is selected from: a direct link, aliphatic hydrocarbylene radicals having up to 20 carbon atoms, which radical may be mono-substituted by hydroxy, (C1-C10)alkoxy, (C1-C10)acyl, (C1-C10)acyloxy, or (C6-C10)aryl, NH, and O, provided that if X is CH2, Y is a direct link; Z is selected from the following groups: (1) H, halo, cyano, (2) hydroxy, (C1-C10)alkoxy, (C1-C10)alkylthio, (C1-C10)acyl, thiophenylcarbonyl, (C1-C10)alkoxycarbonyl, (3) (C1-C10)alkylamino, di(C1-C10)alkylamino, (C6-C10)aryl(C1-C10)alkylamino, provided that Y is not O or NH, (4) unsubstituted vinyl, (C6-C10)aryl, (C3-C8)cycloalkyl and fused benz derivatives thereof, (C7-C10)polycycloalkyl, (C4-C8)cycloalkenyl, (C7-C10)polycycloalkenyl, (5) (C6-C10)aryloxy, (C6-C10)arylthio, (C6-C10)aryl(C1-C10)alkoxy, (C6-C10)aryl(C1-C10)alkylthio, (C3-C8)cycloalkyloxy, (C4-C8)cycloalkenyloxy, (6) heterocyclyl selected from the group consisting of monocyclic radicals and fused polycyclic radicals, wherein said radicals contain a total of from 5 to 14 ring atoms, wherein said radicals contain a total of from 1 to 4 ring heteroatoms independently selected from oxygen, nitrogen, and sulfur, and wherein the individual rings of said radicals may be independently saturated, partially unsaturated, or aromatic, provided that if X is CH2, Z is H or is selected from groups (4) and (6), wherein, when Z contains one or more rings, said rings may each independently bear 0 to 4 substituents independently selected from halo, hydroxy, cyano, nitro, oxo, thioxo, aminosulfonyl, phenyl, phenoxy, phenylthio, halophenylthio, benzyl, benzyloxy, (C1-C10)alkyl, (C1-C10)alkoxy, (C1-C10)alkoxycarbonyl, (C1-C10)alkylthio, (C1-C10)alkylamino, (C1-C10)alkylaminocarbonyl, di(C1-C10)alkylamino, di(C1-C10)alkylaminocarbonyl, di(C1-C10)alkylamino(C1-C10)alkoxy, (C1-C3)perfluoroalkyl, (C1-C3)perfluoroalkoxy, (C1-C10)acyl, (C1-C10)acyloxy, (C1-C10)acyloxy(C1-C10)alkyl, and pyrrolidinyl; and pharmaceutically acceptable salts thereof. This invention relates to compounds which are inhibitors of microsomal triglyceride transfer protein and/or apolipoprotein B (Apo B) secretion, and which are accordingly useful for the prevention and treatment of atherosclerosis and its clinical sequelae, for lowering serum lipids, and related diseases. The invention further relates to compositions comprising the compounds and to methods of treating atherosclerosis, obesity, and related diseases and/or conditions with the compounds.

    Abstract translation: 式（I）化合物，其中X为CH 2，CO，CS或SO 2; Y选自：直接键合，具有至多20个碳原子的脂族亚烃基，该基团可以被羟基，（C1-C10）烷氧基，（C1-C10）酰基，（C1-C10）酰氧基， 或（C 6 -C 10）芳基，NH和O，条件是如果X是CH 2，则Y是直链; Z选自以下基团：（1）H，卤素，氰基，（2）羟基，（C1-C10）烷氧基，（C1-C10）烷硫基，（C1-C10）酰基，苯硫基羰基，（C1-C10） 烷氧基羰基，（3）（C1-C10）烷基氨基，二（C1-C10）烷基氨基，（C6-C10）芳基（C1-C10）烷基氨基，条件是Y不为O或NH，（4）未取代的乙烯基，（C6 -C（C 10）芳基，（C 3 -C 8）环烷基和其稠合苯并衍生物，（C 7 -C 10）多环烷基，（C 4 -C 8）环烯基，（C 7 -C 10）多环烯基，（5） （C 1 -C 10）芳基（C 1 -C 10）烷氧基，（C 6 -C 10）芳基（C 1 -C 10）烷硫基，（C 3 -C 8）环烷氧基，（C 8 -C 8）环链烯氧基，（6） 由单环基团和稠合多环基团组成，其中所述基团含有总共5至14个环原子，其中所述基团含有总共1至4个独立地选自氧，氮和硫的环杂原子，以及 其中所述基团的各个环可以独立地是饱和的，部分不饱和的或芳族的 条件是如果X是CH 2，Z是H或选自基团（4）和（6），其中当Z含有一个或多个环时，所述环各自独立地具有0至4个独立地选自卤素， 羟基，氰基，硝基，氧代，硫代，氨基磺酰基，苯基，苯氧基，苯硫基，卤代苯硫基，苄基，苄氧基，（C1-C10）烷基，（C1-C10）烷氧基，（C1-C10）烷氧羰基，（C1-C10） （C1-C10）烷基氨基，（C1-C10）烷基氨基羰基，二（C1-C10）烷基氨基，二（C1-C10）烷基氨基羰基，二（C1-C10）烷基氨基（C1-C10）烷氧基，（C1-C3） 全氟烷基，（C1-C3）全氟烷氧基，（C1-C10）酰基，（C1-C10）酰氧基，（C1-C10）酰氧基（C1-C10）烷基和吡咯烷基; 及其药学上可接受的盐。 本发明涉及作为微粒体甘油三酯转运蛋白和/或载脂蛋白B（Apo B）分泌抑制剂的化合物，其相应地可用于预防和治疗动脉粥样硬化及其临床后遗症，降低血清脂质和相关疾病。 本发明进一步涉及包含该化合物的组合物以及用该化合物治疗动脉粥样硬化，肥胖症和相关疾病和/或病症的方法。

Patent Agency Ranking